The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications (Q38004705)

26 August 2017

The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications (English)

1 reference

major depressive disorder

26 August 2017

1 reference

2

1 reference

26 August 2017

3

1 reference

26 August 2017

4

1 reference

26 August 2017

S Moylan

1

1 reference

PubMed ID

22525486

26 August 2017

language of work or name

English

0 references

publication date

24 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

18

1 reference

26 August 2017

5

1 reference

26 August 2017

595-606

1 reference

https://scigraph.springernature.com/pub.10.1038/mp.2012.33

26 August 2017

0 references

cites work

Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Symptom predictors of response to electroconvulsive therapy in older patients with treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Volumetric MRI studies of the hippocampus in major depressive disorder: Meanings of inconsistency and directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up.

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FMP.2012.33

21 January 2018

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Hippocampal volume and depression: a meta-analysis of MRI studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Untreated Depression and Hippocampal Volume Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Course of illness, hippocampal function, and hippocampal volume in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cellular changes in the postmortem hippocampus in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Amygdala core nuclei volumes are decreased in recurrent major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Enlargement of the amygdala in patients with a first episode of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Amygdala volumes in mood disorders--meta-analysis of magnetic resonance volumetry studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Anatomical MRI study of basal ganglia in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Smaller cingulate volumes in unipolar depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Volumetric reduction in left subgenual prefrontal cortex in early onset depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Reduced volume of orbitofrontal cortex in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mechanisms of illness progression in the recurrent affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Severity of depressive episodes during the course of depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Recurrence in affective disorder. II. Effect of age and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

One experience with ‘lower’ or ‘higher’ intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Kynurenines impair energy metabolism in rat cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Kynurenines and the respiratory parameters on rat heart mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Quinolinate mimics neurotoxic actions of N-methyl-D-aspartate in rat cerebellar slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interferon-alpha reduces the density of monoaminergic axons in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The role of dopamine in the pathophysiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The association between serum levels of neopterin and number of depressive episodes of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Proinflammatory activity and the sensitization of depressive-like behavior during maternal separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interferon-gamma increases neuronal death in response to amyloid-beta1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neurotoxic consequences of central long-term administration of interleukin-2 in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interleukin-1β Released by gp120 Drives Neural Death through Tyrosine Phosphorylation and Trafficking of NMDA Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cytokines mediated inflammation and decreased neurogenesis in animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neopterin modulates toxicity mediated by reactive oxygen and chloride species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-alpha induced programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The stress system in the human brain in depression and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The HPA axis in major depression: classical theories and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Glucocorticoid receptor function in vitro in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cytokines sing the blues: inflammation and the pathogenesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Glucocorticoids, cytokines and brain abnormalities in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Steroid up-regulation of FKBP51 and its role in hormone signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Lipid peroxidation as a common pathomechanism in coronary heart disease and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Exposure of glia to pro-oxidant agents revealed selective Stat1 activation by H2O2 and Jak2-independent antioxidant features of the Jak2 inhibitor AG490

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Molecular mechanisms and pathophysiology of necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mechanism of alcohol-induced oxidative stress and neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Malonaldehyde acts as a mitochondrial toxin: Inhibitory effects on respiratory function and enzyme activities in isolated rat liver mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

4-Hydroxynonenal in the pathomechanisms of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

4-Hydroxy-2-nonenal induces mitochondrial dysfunction and aberrant axonal outgrowth in adult sensory neurons that mimics features of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Amyloid beta peptide, 4-hydroxynonenal and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Nitric oxide and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased plasma nitric oxide metabolites in suicide attempters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Nitric oxide inhibits the release of norepinephrine and dopamine from the medial basal hypothalamus of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): a feature of its antidepressant activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Alterations of rCBF and mitochondrial dysfunction in major depressive disorder: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Inflammation, mitochondria, and the inhibition of adult neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Activity of mitochondrial respiratory chain is increased by chronic administration of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Transmitochondrial embryonic stem cells containing pathogenic mtDNA mutations are compromised in neuronal differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mitochondria and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Depression, antidepressants, and neurogenesis: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Serum and plasma BDNF levels in major depression: a replication study and meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant-like effects of intracerebroventricular FGF2 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Decreased serum brain-derived neurotrophic factor levels in major depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Decreased plasma BDNF level in depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Epigenetic marking of the BDNF gene by early-life adverse experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Lasting epigenetic influence of early-life adversity on the BDNF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

A "deficient environment" in prenatal life may compromise systems important for cognitive function by affecting BDNF in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The role of BDNF in depression on the basis of its location in the neural circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

S100B's double life: intracellular regulator and extracellular signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Epigenetic programming by maternal behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Serotonin transporter expression is predicted by early life stress and is associated with disinhibited behavior in infant rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neuronal activity modifies the DNA methylation landscape in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Toward an anti-inflammatory strategy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Proteomic analysis of the anti-inflammatory action of minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant-like actions of minocycline combined with several glutamate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Does minocycline have antidepressant effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Long-term statin use and psychological well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Association of Western and traditional diets with depression and anxiety in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Consumption of a palatable diet by chronically stressed rats prevents effects on anxiety-like behavior but increases oxidative stress in a sex-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Omega-3 fatty acids on the forced-swimming test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Chronic ω-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for ω-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Effect of dietary fatty acids on inflammatory gene expression in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant-like effects of N-acetyl-L-cysteine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Immobilization stress induces cell death through production of reactive oxygen species in the mouse cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

A Role for Interferon-Gamma in Focal Cerebral Ischemia in Mice

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FMP.2012.33

21 January 2018

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

A novel biologically active seleno-organic compound—1

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

Lower hippocampal volume in patients suffering from depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Hippocampal volume reduction in major depression.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Degeneration of locus coeruleus axons in stress-induced depression model

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

CSF monoamine metabolites in depression and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Immune disturbances during major depression: upregulated expression of interleukin-2 receptors

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Glucocorticoid Feedback Resistance

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Depression and interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Function and regulation of ras.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Elevated plasma nitrate levels in depressive states

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Mitochondrial energy depletion in depression with somatization

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Mitochondrial inheritance in depression, dysmotility and migraine?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Targeting TrkB neurotrophin receptor to treat depression

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

TNF-α antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

A Meta-Analytic Review of Double-Blind, Placebo-Controlled Trials of Antidepressant Efficacy of Omega-3 Fatty Acids

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.33

7 January 2021

Identifiers

DOI

10.1038/MP.2012.33

1 reference

26 August 2017

1 reference

PubMed ID

22525486